Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-06-18

New Models for Preclinical Evaluation of Drug Efficacy in Common Solid Tumours

Objectif

Traditional preclinical discovery methods, particularly for target validation, poorly predict drug efficacy, causing a high attrition rate in costly late-stage clinical trials. The PREDECT consortium will focus on complex but transferable, next generation in vitro and in vivo models for breast, prostate and lung cancers. Models will be investigated for their improved potential to validate novel therapeutic targets. Known targets, in canonical pathways, will be interrogated for induction of phenotypic, proteomic and transcriptomic changes using inhibitors. A strategy of seeking a ‘dynamic reciprocity’ of concordance between the steady and perturbed states of in vitro complex cultures, tissue slices and in vivo tumour models will be pursued by systems biology analyses. Comparison with historic gene expression and genomic data from relevant clinical materials should permit the emergence of faithful models for target validation and beyond.

PREDECT is coordinated by Servier and AstraZeneca, and the managing entity of IMI JU funding is the University of Helsinki. The team assembles world-class biologists, clinicians and computational scientists from 8 prestigious EU institutes, 3 SMEs and 8 EFPIA members to develop and critically assess models for target validation. The interaction between pharmaceutical and academic participants will be proactive, through postdoc co-supervision and work package co-piloting.

We propose to develop and generate a repository of advanced complex models in 3 complementary areas: (i) in vitro 2D/3D organotypic (co-)cultures, stirred bioreactor aggregates and tissue slice systems; (ii) novel (orthotopic) grafts of human and mouse tumour samples; and (iii) genetically-engineered and mosaic mouse models. The deliverables of PREDECT are expected to shift paradigms in target validation, permitting greater predictivity of drug efficacy in patient cohorts.

Champ scientifique

Programme(s)

Thème(s)

Appel à propositions

IMI-JU-02-2009
Voir d’autres projets de cet appel

Régime de financement

JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)

Coordinateur

INSTITUT DE RECHERCHES SERVIER
Contribution de l’UE
Aucune donnée
Adresse
22 ROUTE 128
91190 GIF-SUR-YVETTE
France

Voir sur la carte
Région
Ile-de-France Ile-de-France Essonne
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Chercheur principal
John Angus HICKMAN (Dr)
Contact administratif
John Angus HICKMAN (Dr)
Liens
Coût total
Aucune donnée

Participants (20)

Partager cette page

Télécharger

Dernière mise à jour: 10 Février 2022

Mon livret

Permalink: https://cordis.europa.eu/project/id/115188/fr

European Union, 2024